Latest news with #Medicare-covered
Yahoo
13-05-2025
- Health
- Yahoo
Trump mentions ‘fat shot drug' in executive order announcement. Will Ozempic get cheaper?
President Donald Trump signed an executive order on May 12 aimed at lowering drug prices to better match what other countries charge. In a White House press conference ahead of his trip to the Middle East, he held a press conference alongside Secretary of Health and Human Services Robert F. Kennedy Jr. During which, he shared a viral anecdote about his friend getting drugs cheaper abroad, illustrating how high drug prices are in the U.S.: nearly three times higher than 33 comparison countries, according to an HHS report. How the executive order will lower prices and by how much remains to be seen, as Trump tried a similar effort in 2020. In the meantime, here is what to know about Trump's "fat shot drug" story. White South Africans arrive in US. Trump's 'genocide' claim disputed. In the press conference, Trump told a story about a friend who complained to him about the difference in drug prices between the U.S. and other countries. "A friend of mine who's a businessman, very, very, very top guy, most of you would have heard of him. Highly neurotic, brilliant businessman, seriously overweight ... and he takes the ... fat shot drug," Trump said. "He called me up and he said, 'President ... I'm in London and I just paid for this damn fat drug I take." "I said, 'It's not working,'" Trump told reporters. "He said: 'I just paid $88 and in New York I pay $1,300. What the hell is going on?" Trump recalled his friend saying. The White House did not immediately respond to a request for comment if the "fat drug" Trump was talking about was Ozempic or another drug to treat diabetes that is also used for weight loss. But the boom in the drugs' popularity has raised concerns that the US is returning to an age of widespread body image issues and fat shaming. In 2020, Trump announced the "Most Favored Nation" system, which would have made an international reference price for some Medicare-covered drugs. The order was later blocked in court. In 2022, President Joe Biden signed the Inflation Reduction Act, which expanded Medicare benefits to cap out-of-pocket drug prices and insulin and allows the federal government to negotiate Medicare's most expensive drug prices. Ozempic and Wegovy were put up for negotiation earlier this year and the cost cuts were previously scheduled to go into effect in 2027. Trump's executive order builds on his original policy by also including Medicaid and private sector insurance, USA TODAY reported. It gives drugmakers price targets and threatens to take further action if the companies do not make "significant progress" in the first six months. Trump said the price cut targets could range anywhere from 59% to 90%. Reuters and The Hill reported that the White House said weight loss drugs are likely to be a part of the drugs the president wants to bring prices down on. The White House also said the existing negotiations were not enough. Contributing: Hannah Yasharoff, Swapna Venugopal Ramaswamy, Ken Alltucker, USA TODAY Kinsey Crowley is the Trump Connect reporter for the USA TODAY Network. Reach her at kcrowley@ Follow her on X and TikTok @kinseycrowley or Bluesky at @ This article originally appeared on Palm Beach Post: Trump 'fat shot drug:' Will weight loss drugs get cheaper under EO?
Miami Herald
11-05-2025
- Health
- Miami Herald
Trump proposes major Medicare drug plan changes
President Donald Trump is expected to sign an executive order soon to lower the cost of prescription drugs for Medicare beneficiaries. The order would implement a "most favored nation" policy, tying the prices of certain Medicare-covered drugs to those paid by other developed countries. The goal: bring U.S. prices more in line with international norms by leveraging the administration's executive authority. For the 53 million people enrolled in Medicare Part D-out of the 67.3 million total Medicare beneficiaries-this move could offer meaningful relief from high out-of-pocket drug costs. Don't miss the move: SIGN UP for TheStreet's FREE daily newsletter U.S. prescription drug prices in 2022 were nearly three times higher than those in 33 other developed countries, and brand-name drugs cost over four times more and more than three times higher after rebates, according to 2024 RAND Corporation report for the Department of Health and Human Services (HHS). And KFF showed U.S. per capita drug spending was more than double that of comparable countries, $1,126 vs. $552, according to 2019 data. UnSplash During his first term, President Trump pushed a similar plan to cut prescription drug costs, but a federal judge blocked the effort before it could take effect. "People may have forgotten that President Trump initiated the 'American Patients First' blueprint in May of 2018, which aimed to lower drug prices and reduce out of pocket costs for Americans," says Diane Daniels, founder of Medicare Nation. "In 2020, Trump rolled out the 'Senior Savings Model,' the pilot program where a set of formulary insulins were set at a maximum $35 copayment per month's supply." Related: How the IRS taxes Social Security income in retirement According to Daniels, Medicare Advantage plans and stand-alone prescription drug plans offered the Senior Savings Model in January 2021, with five pharmaceutical manufacturers participating. Daniels said that the model has been instrumental in laying the groundwork for implementing the Inflation Reduction Act of 2022, which allowed HHS to negotiate with drug manufacturers. If enacted, President Trump's executive order could mark another significant turn in Medicare drug pricing policy, adding to federal efforts to control prescription costs. The IRA set the stage, requiring the HHS Secretary to negotiate prices for select high-cost drugs. In fact, Medicare has already negotiated lower prices for 10 prescription drugs under the IRA. These drugs are: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, and Imbruvica. "Starting in January of 2026, 10 Medicare Part D negotiated prescription medications are set to offer beneficiaries a 38%-79% discount on these medications," said Daniels. Related: These are the most tax-friendly states if you work in retirement The IRA also introduced a $2,000 annual cap on out-of-pocket costs beginning in 2025; eliminated the 5% coinsurance requirement in the catastrophic phase starting in 2024; and capped monthly insulin costs. These reforms were expected to benefit beneficiaries with the highest drug costs-typically older adults with multiple chronic conditions. According to AARP, nearly 75% of those who will benefit from the $2,000 cap are between the ages of 65 and 84, with 45.6% between 75 and 84 and 29.8% between 65 and 74. "Beginning this, persons with Medicare Part D plans have a $2,000 annual cap on out-of-pocket costs for covered medications," said Tom Clark, a Social Security and Medicare consultant. "As long as they pick a Part D plan that covers all their medications, they are already fairly well protected against high drug costs." These reforms were expected to benefit beneficiaries with the highest drug costs, typically older adults with multiple chronic conditions. Nearly 75% of those who will benefit from the $2,000 cap fall between the ages of 65 and 84, with 45.6% between 75 and 84 and 29.8% between 65 and 74, according to AARP. Related: Medicare recipients face a growing problem While numerous studies have shed light on out-of-pocket drug costs, much of the data predates the full rollout of the IRA. For instance, an Employee Benefit Research Institute study published in 2016 showed the following: For single households, average biennial out-of-pocket prescription drug costs were $1,721 for ages 65-74,$1,763 for ages 75-84, and$1,846 for ages 85 and older. For couple households, these figures were $3,233 (65-74),$3,156 (75-84), and$3,442 (85+). The potential implementation of the "most favored nation" approach could have far-reaching implications for Medicare beneficiaries. Not surprisingly, the pharmaceutical industry has historically opposed such pricing reforms while consumer advocates argue that this pricing policy could lower costs for some of Medicare's priciest drugs. "Trump's executive order will expand access to lower cost drugs imported from outside of the country, which has predominantly been a ball of red tape," said Daniels. "How the executive order will work alongside current tariffs is another issue." She also said that Medicare Advantage carriers have not responded well to the current Medicare Part D $2,000 maximum out-of-pocket cost for Medicare beneficiaries. "Many Medicare Advantage Plan carriers, looking to regain lost profit, reduced non-Medicare benefits like dental, eyeglass allowance and hearing aid allowances," said Daniels. "Some carriers introduced 'medical deductibles' in their plans, moved some Part D medications to higher tiers and increased monthly premiums on certain Medicare Advantage plans." Tom Wright, President of The Turning 65 Workshop, offers a more measured assessment: "From a 'big picture' perspective there's a large divide between the majority of retirees for whom this will not likely be of any consequence in the near term (if at all), and a much smaller subset of those who take a medication(s) that might be directly impacted in a material way." Wright cautions against premature action. "For that smaller subset of retirees, since the executive order has yet to be issued - and pharmaceutical companies have yet to respond - it's premature to initiate any kind of research into alternatives," he said. "Given the likely extended timeline of any implementation, I would simply advise retirees who have significant Medicare prescription needs to be aware of this issue and that there may eventually be a need to re-evaluate their drug plan choice... something they should normally do on an annual basis anyway." Here's what Medicare beneficiaries should consider: Stay informed: Pay attention to announcements from the administration and Medicare about potential changes to drug pricing that could affect your your coverage: Review your current Medicare prescription drug coverage (Part D) and understand which of your medications have restrictions or high healthcare providers: Daniels recommends that Medicare beneficiaries should bring a copy of their 'drug formulary' to doctor appointments. "This allows doctors to look up classification of drugs and discuss options more favorably with patients," she for details: Wright suggests that any future changes will be communicated in detail to Medicare drug plan members when the time eventually comes. "With all the anxiety and uncertainty happening in the world, there's currently no need for an issue like this to add to a retiree's stress level," said Medicare plan choices: During the next Medicare annual election period, the impact of this policy might influence which plan offers the best coverage for your needs. Got questions about retirement? Email Learn more about Medicare. The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
26-02-2025
- Business
- Yahoo
Biodesix to Present at TD Cowen 45th Annual Health Care Conference
BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at TD Cowen 45th Annual Health Care Conference on March 5, 2025. TD Cowen 45th Annual Health Care ConferenceFireside Chat Date: Wednesday, March 5, 2025Fireside Chat Time: 1:50 PM ETLocation: Boston, MA The presentation will be webcast live and available for replay under 'News & Events' in the Investors section of the Company's website at About Biodesix Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for pulmonology patients. The Nodify Lung® Nodule Risk Assessment evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The IQLung™ test portfolio for lung cancer patients supports treatment decisions across all stages of lung cancer and expedites personalized treatment. In addition, Biodesix collaborates with the world's leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc. Contacts: Media:Natalie St. Investors:Chris
Associated Press
04-02-2025
- Health
- Associated Press
MoodRx Launches Silver Lining Clinics on Valentine's Day 2025 with Free Therapy for Medicare Beneficiaries
'Silver Lining Clinics is more than therapy—it's hope. This Valentine's Day, we're showing seniors the love they deserve by making mental health care free and life-changing.' — Kruti Quazi, LPC - CEO MoodRx LLC WAYNE, PA, UNITED STATES, February 4, 2025 / / -- – In a groundbreaking move to support the mental well-being of Pennsylvania's aging population, Silver Lining Clinics LLC a subsidiary of MoodRx LLC, is launching on February 14, 2025. This revolutionary mental health service offers Medicare-covered therapy with no co-pays after deductibles, making quality care accessible to seniors who need it most. This initiative comes at a critical time, as senior mental health issues reach unprecedented levels. A Mission of Compassion and Change Aging isn't just about physical health—it's an emotional and mental journey filled with unique challenges. The loss of loved ones, chronic illness, financial instability, and isolation create a perfect storm for depression, anxiety, and cognitive decline. Unfortunately, mental health support remains one of the most overlooked aspects of senior care. That's why Silver Lining Clinics is stepping in to fill this urgent gap, providing accessible, compassionate, and life-changing therapy for seniors and their families. The launch coinciding with Valentine's Day is no accident—this initiative is all about showing love where it's needed most. The Mental Health Crisis Facing Seniors and Their Families The numbers are staggering: • One in five seniors experience mental health issues, yet only 50% receive the care they need. • Loneliness increases the risk of death by 26%, and social isolation is as harmful as smoking 15 cigarettes a day. • More than six million Americans suffer from Alzheimer's or dementia, with caregivers bearing an immense emotional and physical burden. Beyond statistics, these challenges manifest in heartbreaking ways—grieving spouses struggling to find joy, isolated seniors with no one to talk to, caregivers battling exhaustion, and families grappling with tough decisions. Silver Lining Clinics: The Solution Seniors Desperately Need What Sets Us Apart? • No out-of-pocket cost for Therapy for Medicare Beneficiaries – Making quality mental health care truly accessible. • Tailored Support for Seniors – Therapists trained to address age-specific challenges. • Help for Families and Caregivers – Because senior mental health affects everyone around them. • In-Person & Virtual Options in Pennsylvania – Flexibility to meet seniors where they are. Getting Started is Simple: • Register for Free – Sign up at or call/text 863-320-2545. • The Match – Get paired with a therapist specializing in senior care. • Start Healing – Attend sessions in person or online from the comfort of home. Our Expert Therapists Cover a Wide Range of Issues: • Grief & Bereavement • Depression & Anxiety • Dementia & Cognitive Issues • Social Isolation & Loneliness • Sleep Disorders • Caregiver Support • Chronic Stress & Mood Disorders • A Lifeline for Families and Caregivers Caregivers often carry the emotional burden of their loved ones' struggles, leading to burnout, guilt, and overwhelming stress. Silver Lining Clinics isn't just for seniors — we're here to support their families, too. Our services help caregivers: • Cope with stress and burnout • Navigate difficult conversations about care • Find balance between work, family, and caregiving responsibilities • Affordable and Accessible Mental Health Care • Medicare: Free therapy (no out-of-pocket costs) for eligible Pennsylvania residents. • Insurance: We also accept Aetna, Optum (United Healthcare), Quest Behavioral Health, Ambetter, and Magellan. Why Journalists Should Cover This Story • A Valentine's Day Launch That's More Than Just Romance – This initiative brings love and healing where it's needed most. • A National Crisis with a Local Solution – Pennsylvania's seniors finally have a mental health service tailored just for them. • Compelling Human Interest Stories – Families, caregivers, and seniors will share how therapy transformed their lives. • A Call to Action for Policymakers – Highlighting the need for more mental health resources for the aging population. • Silver Lining Clinics is not just another healthcare provider—it's a movement for change. • For exclusive interviews and in-depth insights, journalists can contact us at [email protected] or call 863-320-2545. About Silver Lining Clinics Silver Lining Clinics, powered by MoodRx LLC, is dedicated to transforming the way seniors and their caregivers experience mental health care. With a mission to eliminate cost barriers to therapy, the clinic provides compassionate, expert-led services that promote healing, resilience, and joy in aging by providing no co-pay therapy for Medicare members on Medicare Part B after their annual deductible has been met. Sami Quazi
